Neurology 2003;60:927-934
© 2003 American Academy of Neurology
Controlled-release oxycodone for pain in diabetic neuropathy
A randomized controlled trial
Joseph S. Gimbel, MD,
Patricia Richards, MD PhD and
Russell K. Portenoy, MD
From the Arizona Research Center, LLC (Dr. Gimbel), Phoenix; Purdue Pharma L.P. (Dr. Richards), Stamford, CT; and the Department of Pain Medicine and Palliative Care (Dr. Portenoy), Beth Israel Medical Center, New York, NY.
Address correspondence and reprint requests to Dr. Patricia Richards, Purdue Pharma L.P., One Stamford Forum, Stamford, CT 06901-3431; e-mail: patricia.richards{at}pharma.com
Background and objective: Opioid treatment has played a limited role in the management of diabetic neuropathy, in part because of concerns about the responsiveness of neuropathic pain to opioid treatment. This controlled study evaluated the efficacy and safety of controlled-release (CR) oxycodone in subjects with moderate to severe pain due to diabetic neuropathy.
Methods: This multicenter, randomized, double-blind, placebo-controlled, parallel-group study included 159 subjects with moderate to severe pain due to diabetic neuropathy. Treatment began with either one 10-mg tablet of CR oxycodone (n = 82) or identical placebo (n = 77) every 12 hours. Doses could be increased every 3 days to a maximum of 6 tablets (60 mg CR oxycodone) every 12 hours. Treatment lasted up to 6 weeks. The primary efficacy variable was overall average daily pain intensity during study days 28 to 42.
Results: At an average (SD) dose of 37 (21) mg per day (range 10 to 99 mg/d), CR oxycodone provided more analgesia than placebo (p= 0.002) in the intent-to-treat cohort. From days 28 to 42, overall average daily pain intensity (least squares mean ±SE), rated in subject diaries on a numeric scale of 0 (no pain) to 10 (pain as bad as you can imagine), was 4.1 ± 0.3 in subjects given CR oxycodone and 5.3 ± 0.3 in placebo-treated subjects. Overall, 80 (96%) of 82 subjects given CR oxycodone and 52 (68%) of 77 subjects who received placebo reported adverse events. The most common adverse events in the CR oxycodone group were opioid related.
Conclusions: In this 6-week trial, CR oxycodone was effective for the treatment of moderate to severe pain due to diabetic neuropathy. Adverse events were typical of opioid-related side effects.
This article has been cited by other articles:
|
|
|
|
 
S. Tesfaye and D. Selvarajah
Recent advances in the pharmacological management of painful diabetic neuropathy
The British Journal of Diabetes & Vascular Disease,
November 1, 2009;
9(6):
283 - 287.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Ziegler
Painful Diabetic Neuropathy: Advantage of novel drugs over old drugs?
Diabetes Care,
November 1, 2009;
32(suppl_2):
S414 - S419.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Rutkove
A 52-Year-Old Woman With Disabling Peripheral Neuropathy: Review of Diabetic Polyneuropathy
JAMA,
October 7, 2009;
302(13):
1451 - 1458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Devulder, A. Jacobs, U. Richarz, and H. Wiggett
Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain
Br. J. Anaesth.,
October 1, 2009;
103(4):
576 - 585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Passik
Issues in Long-term Opioid Therapy: Unmet Needs, Risks, and Solutions
Mayo Clin. Proc.,
July 1, 2009;
84(7):
593 - 601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Argoff and D. I. Silvershein
A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs
Mayo Clin. Proc.,
July 1, 2009;
84(7):
602 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Van Zee
The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy
Am J Public Health,
February 1, 2009;
99(2):
221 - 227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ziegler
Treatment of Diabetic Neuropathy and Neuropathic Pain: How far have we come?
Diabetes Care,
February 1, 2008;
31(Supplement_2):
S255 - S261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Galluzzi
Managing Neuropathic Pain
J Am Osteopath Assoc,
November 1, 2007;
107(suppl_6):
ES39 - ES48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Smith
Painful Diabetic Peripheral Neuropathy
J Am Podiatr Med Assoc,
September 1, 2007;
97(5):
394 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Abrams
Pharmacologic Treatments for Pain Associated With Diabetic Peripheral Neuropathies
Journal of Pharmacy Practice,
February 1, 2007;
20(1):
103 - 109.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. S Jensen, M.-M. Backonja, S. H. Jimenez, S. Tesfaye, P. Valensi, and D. Ziegler
New perspectives on the management of diabetic peripheral neuropathic pain
Diabetes and Vascular Disease Research,
September 1, 2006;
3(2):
108 - 119.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. Gilron, C. P. N. Watson, C. M. Cahill, and D. E. Moulin
Neuropathic pain: a practical guide for the clinician.
Can. Med. Assoc. J.,
August 1, 2006;
175(3):
265 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Ross, J. Riley, C. Quigley, and K. I. Welsh
Clinical Pharmacology and Pharmacotherapy of Opioid Switching in Cancer Patients
Oncologist,
July 1, 2006;
11(7):
765 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Lemberg, V. K. Kontinen, K. Viljakka, I. Kylanlahti, J. Yli-Kauhaluoma, and E. Kalso
Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat.
Anesth. Analg.,
June 1, 2006;
102(6):
1768 - 1774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Furlan, J. A. Sandoval, A. Mailis-Gagnon, and E. Tunks
Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects.
Can. Med. Assoc. J.,
May 23, 2006;
174(11):
1589 - 1594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Argoff, M.-M. Backonja, M. J. Belgrade, G. J. Bennett, M. R. Clark, B. E. Cole, D. A. Fishbain, G. A. Irving, B. H. McCarberg, and M. J. McLean
Consensus Guidelines: Treatment Planning and Options
Mayo Clin. Proc.,
April 1, 2006;
81(4_Suppl):
S12 - S25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Belgrade, B. E. Cole, B. H. McCarberg, and M. J. McLean
Diabetic Peripheral Neuropathic Pain: Case Studies
Mayo Clin. Proc.,
April 1, 2006;
81(4_Suppl):
S26 - S32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sinatra
Opioid Analgesics in Primary Care: Challenges and New Advances in the Management of Noncancer Pain
J Am Board Fam Med,
March 1, 2006;
19(2):
165 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Dworkin, J. Katz, and M. J. Gitlin
Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain
Neurology,
December 29, 2005;
65(12_suppl_4):
S7 - S19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Rowbotham
Mechanisms of neuropathic pain and their implications for the design of clinical trials
Neurology,
December 29, 2005;
65(12_suppl_4):
S66 - S73.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Rathur and A. J. M. Boulton
Recent advances in the diagnosis and management of diabetic neuropathy
J Bone Joint Surg Br,
December 1, 2005;
87-B(12):
1605 - 1610.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Galluzzi
Management of Neuropathic Pain
J Am Osteopath Assoc,
September 1, 2005;
105(suppl_4):
S12 - S19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Corbett
Practical Management of Patients With Painful Diabetic Neuropathy
The Diabetes Educator,
July 1, 2005;
31(4):
523 - 540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Irving
Contemporary assessment and management of neuropathic pain
Neurology,
June 28, 2005;
64(12_suppl_3):
S21 - S27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Eisenberg, E. D. McNicol, and D. B. Carr
Efficacy and Safety of Opioid Agonists in the Treatment of Neuropathic Pain of Nonmalignant Origin: Systematic Review and Meta-analysis of Randomized Controlled Trials
JAMA,
June 22, 2005;
293(24):
3043 - 3052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Miller, T. A. DeCoster, and M. S. Mizel
What's New in Foot and Ankle Surgery?
J. Bone Joint Surg. Am.,
April 1, 2005;
87(4):
909 - 917.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J.M. Boulton
Management of Diabetic Peripheral Neuropathy
Clin. Diabetes,
January 1, 2005;
23(1):
9 - 15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ziegler
Polyneuropathy in the diabetic patient--update on pathogenesis and management
Nephrol. Dial. Transplant.,
September 1, 2004;
19(9):
2170 - 2175.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Lussier, A. G. Huskey, and R. K. Portenoy
Adjuvant Analgesics in Cancer Pain Management
Oncologist,
September 1, 2004;
9(5):
571 - 591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B Svendsen, T. S Jensen, and F. W Bach
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
BMJ,
July 31, 2004;
329(7460):
253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko
Diabetic Somatic Neuropathies
Diabetes Care,
June 1, 2004;
27(6):
1458 - 1486.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Dworkin, M. Backonja, M. C. Rowbotham, R. R. Allen, C. R. Argoff, G. J. Bennett, M. C. Bushnell, J. T. Farrar, B. S. Galer, J. A. Haythornthwaite, et al.
Advances in Neuropathic Pain: Diagnosis, Mechanisms, and Treatment Recommendations
Arch Neurol,
November 1, 2003;
60(11):
1524 - 1534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Opioids for Neuropathic Pain
Journal Watch Psychiatry,
June 4, 2003;
2003(604):
8 - 8.
[Full Text]
|
|
|
|
|
|
|
Opioids for Neuropathic Pain
Journal Watch (General),
April 22, 2003;
2003(422):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
D. W. Zochodne and M. B. Max
An old acquaintance: Opioids in neuropathic pain
Neurology,
March 25, 2003;
60(6):
894 - 895.
[Full Text]
[PDF]
|
|
|
|
